FDA dealt another blow to opponents of biosimilar indication extrapolation when it stated that there would be no unique post-marketing requirements for products approved under the 351(k) pathway.
Arthritis Advisory Committee members began asking about the post-marketing requirements early during a Feb. 9 meeting on Celltrion Inc.'s...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?